|
Nov 30
|
Elfun Trusts Sheds Qualcomm in Q3, Embraces New Holdings
|
|
Nov 29
|
BioMarin secures hemophilia gene therapy coverage in Germany
|
|
Nov 28
|
BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany
|
|
Nov 28
|
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
|
|
Sep 23
|
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
|
|
Sep 21
|
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
|
|
Sep 11
|
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
|
|
Sep 6
|
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
|
|
May 3
|
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call Transcript
|
|
May 1
|
New Strong Sell Stocks for May 1st
|
|
Apr 27
|
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
|